NCT03436485 - Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer | Biotech Hunter

Enrollment

204

Participants

Timeline

Start Date

March 19, 2018

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Prostate Cancer Metastatic

Interventions

DRUG

ODM-208

co-administered with glucocorticoid and fludrocortisone, orally daily

DRUG

Midazolam

orally

Trial Locations (20)

14203

University at Buffalo, Kaleida Health Great Lakes Cancer Care Collaborative, Buffalo

21201

University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

68114

Nebraska Cancer Specialists, Omaha

92150

Hopital Foch, Suresnes

Unknown

Helsinki University Central Hospital, Helsinki

Tampere University Hospital, Tampere

Institute Bergonié, Bordeaux

Centre Léon Bérard, Lyon

Institute Paoli-Calmettes, Marseille

Institut de cancérologie Strasbourg Europe, Strasbourg

Institut Gustave Roussy, Villejuif

The Rutherford Cancer Centre, North East, Bedlington

The Rutherford Cancer Centre, North West, Liverpool

Charing Cross Hospital, London

The Christie NHS Foundation Trust, Manchester

CF14 2TL

Velindre Cancer Centre, Cardiff

G12 0YN

The Beatson West of Scotland Cancer Centre, Glasgow

SW3 6JJ

Royal Marsden Hospital, London

PR2 9HT

Royal Preston Hospital, Preston

All Listed Sponsors

lead

Orion Corporation, Orion Pharma

INDUSTRY